Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility.

Margaret Wrensch and colleagues report a genome-wide association and replication study for high-grade glioma. They show that common variants in the CDKN2B and RTEL1 regions are associated with risk of this aggressive brain tumor.